Overview

Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

Status:
Terminated
Trial end date:
2008-06-01
Target enrollment:
0
Participant gender:
Female
Summary
The purpose of this study was to evaluate efficacy of 851B gel over a range of concentrations and dosing regimens on high-risk cervical human papillomavirus infection in women.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Takeda
Criteria
Inclusion Criteria:

- Willing to be on acceptable method of birth control

- Have a Pap smear result of LSIL or ASCUS

- Is high risk HPV positive

Exclusion Criteria:

- No evidence of high-grade disease or glandular abnormalities,

- Complete visualization of all lesion margins and the transformation zone,

- No uncontrolled significant medical illness or sexually transmitted infections,

- Taking any restricted medications such as interferon, immunomodulators, cytotoxic
drugs, investigational drugs, steroids.